Trials / Not Yet Recruiting
Not Yet RecruitingNCT07406178
JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL
JY509 Universal NK Cell Injection for the Treatment of Relapsed or Refractory Pediatric B-cell Acute Lymphoblastic Leukemia
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 3 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of JY509 universal NK cell injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | JY509 universal NK cell injection | 3+3 dose escalation trial and dose expansion trial |
Timeline
- Start date
- 2026-01-20
- Primary completion
- 2029-01-01
- Completion
- 2029-04-01
- First posted
- 2026-02-12
- Last updated
- 2026-02-12
Source: ClinicalTrials.gov record NCT07406178. Inclusion in this directory is not an endorsement.